Clinical effect of buffy‐coat vs. apheresis platelet concentrates in patients with severe thrombocytopenia after intensive chemotherapy

Abstract

We can conclude that BC PCs are not inferior to apheresis PCs, and may serve the clinical purposes as well as apheresis PCs harvested by Amicus.

The clinical impact of platelet refractoriness: correlation with bleeding and survival

“…In the first analysis of this study, we already showed that patient‐related factors were the main determinants of transfusion failure, independent of product factors such as storage medium and storage time 16 . This is in agreement with a recently published study showing that storage duration of both buffy‐coat PCs and apheresis PCs only explained for less than 4 percent of the variation in CCI and transfusion interval 20 …”

Supply with Platelet Concentrates from the Point of View of a Blood Donation Service of the Bavarian Red Cross

“…Another argument not to use PCs is the risk of alloimmunization. However, after switching from the platelet-rich plasma Weinauer method to buffy coat-derived platelet concentrates which showed a better product quality in the sense of residual red cell and white cell contamination, and finally after the introduction of 100% leukodepleted products, there is no clinical demonstrable difference in the transfusion outcome [6,7] between APCs und PCs. When deciding between these two products, finally the following 'minor disadvantages' has to be taken into consideration:…”

Wissenschaftliche Erläuterungen zur Stellungnahme „Bewertung von Apherese- und Pool-Thrombozytenkonzentraten“ des AK Blut vom 31.03.2015

“…Eine Aktualisierung des systematischen Reviews der Cochrane Gesellschaft [94] [57,[104][105][106][107][108][109][110][111][112]. Auch das Intervall bis zur nächsten Transfusion unterschied sich nicht [111].…”

“…Auch das Intervall bis zur nächsten Transfusion unterschied sich nicht [111]. Eine Studie mit kleiner Fallzahl bei AML-Patienten nach Stammzelltransplantation zeigte höhere Thrombozytenzahlen nach ATK-Transfusion, aber keinen signifikanten Unterschied der Blutungskomplikationen [109].…”